The global rare biomarkers market is set to grow 14.4% annually, driven by non-invasive testing methods, rising disease cases, and increasing investments in personalized medicine and advanced diagnostics.
Liquid Biopsy - A Potential Tool to Prevent Kidney Transplant Rejections
Liquid biopsy using dd-cfDNA offers a non-invasive, accurate method for early kidney transplant rejection detection.
Liquid biopsy using dd-cfDNA offers a non-invasive, accurate method for early kidney transplant rejection detection.
‘Biomarkers are transforming #healthcare, driving a 14% market growth with the increasing demand for personalized medicine. #cfdna #biomarkers #medindia
’
Advertisement
Why Is This Market Growing?
The market value was about $36.69 billion in 2023. With rising cases of cancer, heart disease, and genetic disorders, doctors need better diagnostic tools for early detection. Biomarkers serve as the key component in early detection and monitoring.Governments and private companies are investing heavily in biomarker research to improve healthcare. In the shift toward personalized medicine by treating individuals with specific treatments, biomarkers have become crucial for diagnosis. New techniques are improving biomarker detection, making tests more accurate and sensitive.
Advertisement
One Liquid Biopsy - Screening for Many Types of Cancer
Single blood test that screens for eight common cancer types and identifies the location of the cancer has been developed at Johns Hopkins Kimmel Cancer Center
Single blood test that screens for eight common cancer types and identifies the location of the cancer has been developed at Johns Hopkins Kimmel Cancer Center
Challenges and regional Market Trends
The technology required to collect and store biomarkers is expensive, making it difficult for low-income countries to access. Handling biomarkers requires highly trained professionals however, they are not available in many regions. Strict government rules for biomarker validation slow down market adoption.North America leads the market due to strong healthcare systems, research funding, and top medical companies in the U.S. and Canada. Europe is improving with strong government regulations supporting biomarker use. Asia-Pacific is the fastest-growing region due to rising cancer cases and increasing healthcare investment in countries like China and India. Latin America, Middle East & Africa show growth potential as more hospitals adopt advanced diagnostic tools.
Early Detection of Type 2 Diabetes Using Micro-RNAs Biomarkers in Blood
The new technology uses micro-RNA biomarkers in the blood, leading to a more accurate identification of people at high risk of type 2 diabetes.
The new technology uses micro-RNA biomarkers in the blood, leading to a more accurate identification of people at high risk of type 2 diabetes.
Key Players in the Market
Companies like Thermo Fisher, Roche, Agilent Technologies, and Qiagen are leading the industry by investing in new products, partnerships, and acquisitions according to the increasing need and demand.With continued research and technological advancements, biomarkers are expected to revolutionize diagnostics and treatment. This growth will improve early disease detection, personalized medicine, and healthcare efficiency worldwide.
Source-Medindia
Blood Biomarkers and Genomics: Powerful Insights into Disease Risk
Discover how blood biomarkers can enhance near-term risk prediction, enabling personalized preventive care for better health outcomes.
Discover how blood biomarkers can enhance near-term risk prediction, enabling personalized preventive care for better health outcomes.
